It is generally accepted that tumors are angiogenesis-dependent. For research and clinical purposes it would be very attractive to have a simple in vitro model that allows a rapid screening of the angiogenic potential of tumors and to study the effect of angiogenic inhibitors. In vitro angiogenesis models were developed, based on endothelial sprouting/tube formation on a collagen gel, using both tumor cell lines and tumor biopsies. Best results were obtained using conditioned medium of tumor cell lines. In this model it was found that the plasminogen fragment lysine binding site 1 (LBS-1) inhibited in vitro endothelial cell sprouting. This is the first demonstration that LBS-1, which includes angiostatin, is inhibitory for new vessel formation in an in vitro angiogenesis model. We conclude that the assay system allows for rapid and reliable screening of angiogenesis inhibitors.

Keywords:
Angiogenesis, Endothelial cells, Lysine binding site 1, Angiostatin
1.
Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4–6.
2.
Folkman J: New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996;32a:2534–2539.
3.
Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM: Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 1987;57:673–686.
4.
Leunig M, Yuan F, Menger MD, Boucher Y, Goetz AE, Messner K, Jain RK: Angiogenesis microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 1992;52:6553–6560.
5.
Lichtenbeld HHC, Muller AD, VanDam-Mieras MCE, Blijham GH: Tumor spheroid-induced vesicle formation on endothelial cells is associated with procoagulant properties. J Cell Sci 1993;106:657–662.
6.
Montesano R: Regulation of angiogenesis in vitro. Eur J Clin Invest 1992;22:504–515.
7.
Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE: Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997;275:547–550.
8.
Jain RK: Barriers to drug delivery in solid tumors. Sci Am 1994;271:58–65.
9.
O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315–328.
10.
Cao Y, Ji RW, Davidson D, Schaller J, Marti D, Söhndal S, McCance SG, O’Reilly MS, Llinás M, Folkman J: Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 1996;271:29461–29467.
11.
Kost C, Benner K, Stockmann A, Linder D, Preissner KT: Limited plasmin proteolysis of vitronectin. Characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor. Eur J Biochem 1996;236:682–688.
12.
Holmgren L, O’Reilly MS, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149–153.
13.
O’Reilly MS, Holmgren L, Chen C, Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689–692.
14.
Carlsson J, Yuhas JM: Liquid-overlay culture of cellular spheroids. Recent Results Cancer Res 1984;95:1–23.
15.
Montesano R, Orci L, Vassalli P: In vitro organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 1983;97:1648–1652.
16.
Löwik CWGM, Alblas MJ, VandeRuit M, Papapoulos SE, Vander Pluijm G: Quantification of adherent and nonadherent cell cultured in 96-well plates using the supravital stain neutral red. Anal Biochem 1993;213:426–433.
17.
Olea N, Villalobos M, Ruiz de Almodóvar JM, Pedraza V: MCF-7 breast cancer cells grown as multicellular spheroids in vitro: Effect of 17β-estradiol. Int J Cancer 1992;50:112–117.
18.
Barendsz-Janson AF, Muller AD, Lichtenbeld HHC, Van Dam-Mieras MCE, Hillen HFP: Cellular arrangement of human breast cancer cell lines determines hemostatic parameters. Tumor Biol, in press.
19.
Lichtenbeld HHC, VanDam-Mieras MCE, Hillen HFP: Tumor angiogenesis: Pathophysiology and clinical significance. Neth J Med 1996;49:42–51.
20.
Griffioen AW, Damen CA, Blijham GH, Groenewegen G: Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 1996;88:667–673.
21.
Engel LW, Young NA: Human breast carcinoma cells in continuous culture: A review. Cancer Res 1978;38:4327–4339.
22.
Soule HD, Vazquez J, Long A, Albert S, Brennan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973;51:1409–1416.
23.
Hackett AJ, Smith HS, Springer EL, Owens RB, Nelson-Rees WA, Riggs JL, Gardner MB: Two syngeneic cell lines from human breast tissue: The aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines. J Natl Cancer Inst 1977;58:1795–1806.
24.
Tom BH, Rutzky LP, Jakstys MM, Oyasu R, Kaye CI, Kahan BD: Human colonic adenocarcinoma cells. Establishment and description of a new line. In Vitro 1976;12:180–191.
25.
Stadler E, Dziadek M: Extracellular matrix penetration by epithelial cells is influenced by quantitative changes in basement membrane components and growth factors. Exp Cell Res 1996;229:360–369.
26.
Sieuwerts AM, Klijn JGM, Foekens JA: Assessment of the invasive potential of human gynecological tumor cell lines with the in vitro Boyden chamber assay: Influences of the ability of cells to migrate through the filter membrane. Clin Exp Metastasis 1997;15:53–62.
27.
Gately S, Twardowski P, Stack MS, Patrick M, Boggio L, Cundiff DL, Schnaper HW, Madison L, Volpert O, Bouck N, Enghild J, Kwaan HC, Soff GA: Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 1996;56:4887–4890.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.